Study B7981040 is a Phase 3 randomized, double-blind, 52-week placebo-controlled, multi center study investigating the efficacy, safety, and tolerability of ritlecitinib in adult and adolescent participants with non segmental vitiligo (both active and stable vitiligo).
A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Vitiligo (Active and Stable)